Ontology highlight
ABSTRACT: Background
The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate.Methods and findings
To assess the impact of HIV-1 subtype and antiretroviral treatment on the distribution of mutations in protease and reverse transcriptase, a binomial response model using subtype and treatment as explanatory variables was used to analyze a large compiled dataset of non-subtype-B HIV-1 sequences. Non-subtype-B sequences from 3,686 persons with well characterized antiretroviral treatment histories were analyzed in comparison to subtype B sequences from 4,769 persons. The non-subtype-B sequences included 461 with subtype A, 1,185 with C, 331 with D, 245 with F, 293 with G, 513 with CRF01_AE, and 618 with CRF02_AG. Each of the 55 known subtype B drug-resistance mutations occurred in at least one non-B isolate, and 44 (80%) of these mutations were significantly associated with antiretroviral treatment in at least one non-B subtype. Conversely, of 67 mutations found to be associated with antiretroviral therapy in at least one non-B subtype, 61 were also associated with antiretroviral therapy in subtype B isolates.Conclusion
Global surveillance and genotypic assessment of drug resistance should focus primarily on the known subtype B drug-resistance mutations.
SUBMITTER: Kantor R
PROVIDER: S-EPMC1087220 | biostudies-literature | 2005 Apr
REPOSITORIES: biostudies-literature
Kantor Rami R Katzenstein David A DA Efron Brad B Carvalho Ana Patricia AP Wynhoven Brian B Cane Patricia P Clarke John J Sirivichayakul Sunee S Soares Marcelo A MA Snoeck Joke J Pillay Candice C Rudich Hagit H Rodrigues Rosangela R Holguin Africa A Ariyoshi Koya K Bouzas Maria Belen MB Cahn Pedro P Sugiura Wataru W Soriano Vincent V Brigido Luis F LF Grossman Zehava Z Morris Lynn L Vandamme Anne-Mieke AM Tanuri Amilcar A Phanuphak Praphan P Weber Jonathan N JN Pillay Deenan D Harrigan P Richard PR Camacho Ricardo R Schapiro Jonathan M JM Shafer Robert W RW
PLoS medicine 20050426 4
<h4>Background</h4>The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate.<h4>Methods and findings</h4>To assess the impact of HIV-1 subtype and antiretroviral treatment on the distribution of mutations in protease and reverse transcriptase, a binomial response model using subtype and treatment as explanatory variables was u ...[more]